ArticleOncotarget2017
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Clinical assessment of urinary prostate cancer antigen 3 in Chinese population: a large-scale, prospective and multicenter study.World journal of surgical oncology · 2024Article
- Predicting prostate cancer progression with a Multi-lncRNA expression-based risk score and nomogram integrating ISUP grading.Non-coding RNA research · 2024Article
- Article
- Article
- Article
- Long non-coding RNA in prostate cancer.American journal of clinical and experimental urology · 2022Review
- Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis.Cancers · 2021Review
- Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization.The Journal of urology · 2021Article
- Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice.International journal of molecular sciences · 2021Review
- A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization.Prostate cancer and prostatic diseases · 2021Article
- Review
- Reference-free transcriptome exploration reveals novel RNAs for prostate cancer diagnosis.Life science alliance · 2019Article
- The long non-coding RNAOncotarget · 2019Article
- Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.Prostate cancer and prostatic diseases · 2019Article
- Identification of Long Noncoding RNA MIR22HG as a Novel Biomarker in Thyroid Cancer.Pathology oncology research : POR · 2019Article
- UBASH3B Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Prostate Cancer.Frontiers in oncology · 2019Article
- How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer?International journal of physiology, pathophysiology and pharmacology · 2019Article
- Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer.Translational oncology · 2018Article
- The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.Oncotarget · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer antigen 3 (
resultsMATERIALS AND
methodsA total of 1,694 expression profiles from biopsy and 10,382 from RP patients with high risk tumors were obtained from the Decipher Genomic Resource Information Database (GRIDTM)prostate cancer database. The primary clinical endpoint was distant metastasis-free survival for RP and high Gleason grade for biopsy. Logistic regression analyses and Cox proportional hazards models were used to evaluate the association of
conclusionsThere is high prevalence of high grade tumors with low
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.